Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Income from Non-Controlling Interests came in at -$1415.0 in Q1 2026, up 69.68% year-on-year from -$833.92 in Q1 2025, and up 85.97% on a QoQ basis from -$10084.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$1415.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 69.68% year-over-year to -$1415.0 in Q1 2026; TTM through Mar 2026 was -$26257.0, a 80.22% increase from a year earlier, with the FY2025 full-year figure at -$29509.0, up 87.8% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$1415.0, up from -$10084.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for EPRX reached as high as -$1415.0 in Q1 2026 and fell as low as -$380394.0 in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged -$78314.4 across 4 years, with a median of -$47995.0 in 2024.
- Across the five-year window, Income from Non-Controlling Interests plunged 87.65% in 2024 and jumped 95.9% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$380394.0 in 2023, then jumped by 93.85% to -$23385.0 in 2024, then soared by 56.88% to -$10084.0 in 2025, then surged by 85.97% to -$1415.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$1415.0 in Q1 2026, -$10084.0 in Q4 2025, and -$7991.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | -1,415.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,415.00 |
| Dec 31, 2025 | -10,084.00 |
| Sep 30, 2025 | -7,991.00 |
| Jun 30, 2025 | -6,767.00 |
| Mar 31, 2025 | -4,667.00 |
| Dec 31, 2024 | -23,385.00 |
| Sep 30, 2024 | -47,995.00 |
| Jun 30, 2024 | -56,678.00 |
| Mar 31, 2024 | -113,895.00 |
| Dec 31, 2023 | -380,394.00 |
| Sep 30, 2023 | -174,741.00 |
| Jun 30, 2023 | -129,379.00 |
| Mar 31, 2023 | -60,696.00 |